MedTech Dive November 16, 2022
Elise Reuter

At-home tests, once considered an anomaly, became de rigueur and a boon for diagnostic companies during the COVID-19 pandemic.

Now, as COVID-19 testing rates decline from their pandemic peak, these businesses see an opportunity in direct-to-consumer testing, a market that Quest Diagnostics says could total $2 billion by 2025.

“Never before has the general population been more aware of in vitro diagnostics and the relevance of our industry than in the last two years with COVID-19,” Jenna Urquhart, head of new franchise business development for Siemens Healthineers, said in an email. “Thanks to the prevalence of rapid antigen tests, people have learned that it is possible to collect a sample, run a test, and receive results in minutes, all...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Home, Medical Devices, Patient / Consumer, Provider
Related Articles:
Exo adds FDA-cleared AI tools to handheld ultrasound system
FDA spends $1.2M on VR-enabled hub to spur development of at-home care devices
FDA launches initiative to advance home healthcare models, devices
Is Telepathy Possible? Perhaps, Due To New Technology
FDA Proposes Updated Guidance Concerning Cybersecurity of Medical Devices

Share This Article